logo-loader
Redx Pharma Plc

New Redx CEO bringing leadership and skills to 'capitalise on its great science'

Lisa Anson, the new chief executive at Redx Pharma Plc (LON:REDX), sat down with Proactive's Andrew Scott just weeks after taking on the new role.

Anson was the president of AstraZeneca PLC’s (LON:AZN) UK division immediately prior to joining, while she's also held various other senior leadership roles during her 20-year career at the FTSE 100-drugs giant.

The first patient in a Phase I/II trial for Redx's lead drug RXC004 was dosed back in February but they paused the study just over a month later, admitting that the dosing levels it had thought were right based on pre-clinical research were actually too high.

Since then it has been talking with regulators about lowering the dose and getting the trial back up and running again which it expects will happen in the first half of 2019.

Quick facts: Redx Pharma Plc

Price: £0.09

Market: AIM
Market Cap: £10.75 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redx Pharma Plc named herein, including the promotion by the Company of Redx Pharma Plc in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Redx Pharma gets green light to increase dose in lead cancer drug trial

Redx Pharma PLC (LON:REDX) CEO Lisa Anson spoke to Proactive London's Andrew Scott following the news they've been given the go-ahead to up the dose of its lead cancer drug. It comes after the firm successfully navigated the first part of its early-stage trial for RXC004. The asset's part...

on 20/8/19

2 min read

;